Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025)
Immuron (IMRN) posted quarterly Total Non-Current Liabilities of $945.77 for Q3 2025, down 33.18% year-on-year from $1415.5 in Q3 2024, and down 98.58% on a QoQ basis from $66792.6 in Q2 2025.
Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
Immuron (IMRN) has reported Total Non-Current Liabilities for 8 consecutive years, with $945.77 the latest figure, recorded in Q3 2025.
- Quarterly Total Non-Current Liabilities fell 33.18% year-over-year to $945.77 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $945.77 (down 33.18% YoY) and the FY2025 annual result came in at $945.77, down 33.18% from the prior year.
- Total Non-Current Liabilities slipped to $945.77 in Q3 2025 per IMRN's latest filing, from $66792.6 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for IMRN reached as high as $152207.0 in Q2 2023 and fell as low as $934.04 in Q4 2023.
- A 5-year average of $66128.6 and a median of $69240.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 7733.81% — and 2023, when it plunged 99.25%.
- Year by year, Total Non-Current Liabilities stood at $25562.5 in 2021, then surged by 384.71% to $123905.0 in 2022, then tumbled by 99.25% to $934.04 in 2023, then soared by 7575.0% to $71687.5 in 2024, then plunged by 98.68% to $945.77 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $945.77, $66792.6, and $71687.5 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | 945.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 945.77 |
| Jun 30, 2025 | 66,792.61 |
| Dec 31, 2024 | 71,687.45 |
| Sep 9, 2024 | 1,415.46 |
| Jun 30, 2024 | 99,963.28 |
| Dec 31, 2023 | 934.04 |
| Sep 28, 2023 | 107,492.34 |
| Aug 30, 2023 | 1,522.07 |
| Jun 30, 2023 | 152,207.00 |
| Dec 31, 2022 | 123,905.00 |
| Aug 31, 2022 | 123,905.00 |
| Jun 30, 2022 | 123,905.00 |
| Dec 31, 2021 | 25,562.51 |
| Jun 30, 2021 | 25,562.51 |
| Dec 31, 2020 | 326.31 |
| Sep 1, 2020 | 41,839.00 |
| Jun 30, 2020 | 29,547.73 |
| Dec 31, 2019 | 418.39 |
| Jun 30, 2019 | 14,980.00 |
| Dec 31, 2017 | 1.66 Mn |